Barclays PLC Grows Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM)

Barclays PLC boosted its holdings in shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) by 3,661,933.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 549,305 shares of the company’s stock after purchasing an additional 549,290 shares during the period. Barclays PLC owned approximately 1.32% of Carisma Therapeutics worth $539,000 as of its most recent filing with the SEC.

Separately, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Carisma Therapeutics during the second quarter worth about $40,000. 44.27% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the company. BTIG Research downgraded Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 10th. Evercore ISI restated an “in-line” rating and set a $0.70 price target (down previously from $4.00) on shares of Carisma Therapeutics in a research note on Wednesday, December 11th. EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a report on Wednesday, October 30th. Baird R W cut shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, HC Wainwright restated a “neutral” rating on shares of Carisma Therapeutics in a research note on Monday, December 16th. Five research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Carisma Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $4.94.

Carisma Therapeutics Trading Up 5.1 %

Shares of CARM stock opened at $0.44 on Friday. The business’s fifty day moving average price is $0.75 and its 200 day moving average price is $0.96. The firm has a market capitalization of $18.37 million, a PE ratio of -0.28 and a beta of 1.44. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23. Carisma Therapeutics, Inc. has a 1-year low of $0.38 and a 1-year high of $2.94.

Carisma Therapeutics (NASDAQ:CARM) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.31). Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. The business had revenue of $3.39 million for the quarter. As a group, sell-side analysts forecast that Carisma Therapeutics, Inc. will post -1.32 EPS for the current fiscal year.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.